Aktie A2N7B4 LOGICBIO THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen LogicBio Therapeutics, Inc.

Aktien

A2N7B4

US54142F1021

LOGC

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
CANbridge Pharmaceuticals Inc. Announces Update on Collaborations with the Umass Chan Medical School and with Logicbio Therapeutics
LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from S&P TMI Index
Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio Therapeutics
LOGICBIO THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
LogicBio Therapeutics, Inc. Announces Management Changes
AstraZeneca Unit Completes Acquisition of LogicBio Therapeutics
LogicBio Therapeutics, Inc.(NasdaqGM:LOGC) dropped from NASDAQ Composite Index
Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.
LogicBio Therapeutics : Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet - Definitive merger agreement with Alexion, AstraZeneca Rare Disease, to acquire LogicBio with transaction - Form 8-K
LOGICBIO THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
LogicBio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
LOGICBIO THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
LogicBio Therapeutics: Q3 Earnings Snapshot
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Revenue $2.7M
Earnings Flash (LOGC) LOGICBIO THERAPEUTICS Posts Q3 Loss $-0.18
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
LOGICBIO THERAPEUTICS, INC. : Other Events (form 8-K)
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC
LOGICBIO THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)
LogicBio Therapeutics, Inc. and CANbridge Care Pharma Hong Kong Limited Enter into the Amended and Restated Exclusive Research Collaboration, License and Option Agreement
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2N7B4 Aktie
  4. Nachrichten LogicBio Therapeutics, Inc.
  5. Andere Sprachen